Ajax's lead program, AJ1-11095, is a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept clinical data to be presented later in 2026 Based on its unique mode of binding JAK2, AJ1-11095 has the potential to deliver deeper and more...
Hence then, the article about lilly to acquire ajax therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera )
Also on site :
- The rise of ‘conspicuous waiting’: The 19th-century economic theory that explains why Gen Z posts their place in line
- Oscar Mayer Turned a Viral TikTok Trend Into a Real Cake for the Wienermobile's 90th—Here's How to Get It
- PHH, BYAH Investors Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit